Free Trial
→ Real Americans Don’t Wait on Wall Street’s Next Move (From Premier Gold Co) (Ad)
NASDAQ:SILO

Silo Pharma 11/12/2024 Earnings Report

Silo Pharma logo
$1.07 +0.04 (+4.35%)
Closing price 04/17/2025 03:56 PM Eastern
Extended Trading
$1.06 -0.02 (-1.75%)
As of 04/17/2025 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Earnings History

Silo Pharma EPS Results

Actual EPS
-$0.22
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Silo Pharma Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Silo Pharma Announcement Details

Quarter
Date
11/12/2024
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Silo Pharma's next earnings date is estimated for Monday, May 12, 2025, based on past reporting schedules.

Conference Call Resources

Silo Pharma Earnings Headlines

Silo Pharma announces first dosing in IND-enabling study for SPC-15
March 27, 2025 | markets.businessinsider.com
Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
March 26, 2025 | globenewswire.com
Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
April 19, 2025 | Colonial Metals (Ad)
Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment
February 26, 2025 | globenewswire.com
Silo Pharma files provisional patent for SPC-15 combination
February 19, 2025 | markets.businessinsider.com
Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment
February 18, 2025 | globenewswire.com
See More Silo Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Silo Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silo Pharma and other key companies, straight to your email.

About Silo Pharma

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma (NASDAQ:SILO) in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

View Silo Pharma Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles